---
title: 'Peripheral T-cell lymphoma: Are all patients high-risk?'
date: '2023-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38142400/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231225170640&v=2.18.0
source: Blood
description: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature
  T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL).
  Outcomes for the majority of patients with PTCL are poor and treatment approaches
  have been relatively uniform using CHOP based therapy. For example, large registry
  studies consistently demonstrate 5-year overall survival (OS) of approximately 30-40%.
  However, as our understanding of the biology underpinning the heterogeneity of ...
disable_comments: true
---
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL). Outcomes for the majority of patients with PTCL are poor and treatment approaches have been relatively uniform using CHOP based therapy. For example, large registry studies consistently demonstrate 5-year overall survival (OS) of approximately 30-40%. However, as our understanding of the biology underpinning the heterogeneity of ...